Uncategorized
AMA: Fundamentals of drug pricing must be altered
To address and improve the current prescription drug pricing issue in the U.S. market, drugs should be priced based on value, thereby reducing costs without compromising patient outcomes and access, according to a new policy adopted by the AMA.“The new AMA policy acknowledges the carte blanche approach to drug pricing needs to change to align with the health system’s drive for high-quality care based on value,” Andrew W. Gurman, MD, president of the AMA, said in a press release. “This transformation should support drug prices based on overall benefit to (Read more...)